Patents for A61P 35 - Antineoplastic agents (221,099)
05/2011
05/26/2011US20110124691 Organic Compounds
05/26/2011US20110124690 Compositions and methods for treating cancer or a neurotrophic disorder
05/26/2011US20110124688 Nicotine receptor agonists in stem cell and progenitor cell recruitment
05/26/2011US20110124686 Sultam derivatives
05/26/2011US20110124684 Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase
05/26/2011US20110124680 Novel anthranilamide pyridinureas as vascular endothelial growth factor (vegf) receptor kinase inhibitors
05/26/2011US20110124673 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
05/26/2011US20110124668 Novel indole derivative having, carbamoyl group, ureido group and substituted oxy group
05/26/2011US20110124664 Polycationic Compounds And Uses Thereof
05/26/2011US20110124654 Diazacarbazoles and methods of use
05/26/2011US20110124653 Aryl-sulphonamidic dimers as metalloproteases inhibitors
05/26/2011US20110124650 Stable crystalline salts of antifolate compounds
05/26/2011US20110124649 Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
05/26/2011US20110124646 Novel cyclic compound having pyrimidinylalkylthio group
05/26/2011US20110124645 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses
05/26/2011US20110124643 Pyridinopyridinone derivatives, preparation thereof and therapeutic use thereof
05/26/2011US20110124641 Benzothiazole kinase inhibitors and methods of use
05/26/2011US20110124640 Fused heterocyclic compounds useful as kinase modulators
05/26/2011US20110124638 Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors
05/26/2011US20110124636 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
05/26/2011US20110124634 Bioactive compounds for treatment of cancer and neurodegenerative diseases
05/26/2011US20110124632 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
05/26/2011US20110124630 Stemonamide synthesis intermediate and pharmaceutical composition for prevention and/or treatment of cancer
05/26/2011US20110124628 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
05/26/2011US20110124624 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory diseases
05/26/2011US20110124623 Pyrrolotriazine kinase inhibitors
05/26/2011US20110124622 Isoindolones derivatives as mek kinase inhibitors and methods of use
05/26/2011US20110124619 Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators
05/26/2011US20110124603 Trioxane Dimer Sulfur Compounds
05/26/2011US20110124602 Stat3 Inhibitor Having Anti-Cancer Activity and Methods
05/26/2011US20110124585 Dimeric Small Molecule Potentiators of Apoptosis
05/26/2011US20110124582 Novel polypeptide having anti-tumor activity
05/26/2011US20110124580 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto
05/26/2011US20110124574 Restoration of estrogen receptor-(alpha) activity
05/26/2011US20110124572 Syndecan-4 is a regulator of rac1-gtp
05/26/2011US20110124566 Anti-tumor fibrillar human serum albumin methods and compositions
05/26/2011US20110124564 Nucleolin-binding peptides, nucleolin- binding lytic peptides, fusion constructs and methods of making and using same
05/26/2011US20110124558 Novel uses of d-mannopyranose derivatives activating angiogenesis
05/26/2011US20110124552 GMCSF and Truncated CCL2 Conjugates and Methods and Uses Thereof
05/26/2011US20110123702 Room temperature-curable polymers
05/26/2011US20110123651 Dietary supplement drink for delivery of resveratrol and other polyphenols
05/26/2011US20110123646 Extracts Obtained from Cell Line Cultures from Plants Belonging to the Oleaceae Family (e.g. Syringa Vulgaris), Their Preparation and Use
05/26/2011US20110123644 Macrocyclic compounds and methods of treatment
05/26/2011US20110123632 Nanoscale Adjuvants and Related Pharmaceutical Compositions and Methods
05/26/2011US20110123629 Targeting of innate immune response to tumor site
05/26/2011US20110123620 Silicon dioxide nanoparticles and the use thereof for vaccination
05/26/2011US20110123619 Buccal delivery system
05/26/2011US20110123617 Clioquinol for the treatment of hematological malignancies
05/26/2011US20110123603 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
05/26/2011US20110123602 Molecular lymphatic mapping of sentinel lymph nodes
05/26/2011US20110123593 Self-fixating scaffolds
05/26/2011US20110123591 Tumoricidal, bactericidal, or viricidal macrophage activation
05/26/2011US20110123576 Intestinal environment-improving agent
05/26/2011US20110123562 Anti-cancer active substance from antrodia camphorata, method for preparing the same and use thereof
05/26/2011US20110123554 Uses of immunoconjugates targeting cd138
05/26/2011US20110123552 Agonistic binding molecules to the human OX40 receptor
05/26/2011US20110123551 Hvem/btla, hvem/cd 160 and hvem/gd cis complexes and methods of use
05/26/2011US20110123550 Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers
05/26/2011US20110123549 Antibodies to EphA3
05/26/2011US20110123545 Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
05/26/2011US20110123544 Human antibodies that bind human il-12 and methods for producing
05/26/2011US20110123542 Ccl20-specific antibodies for cancer therapy
05/26/2011US20110123539 Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
05/26/2011US20110123537 Binding epitopes for g250 antibody
05/26/2011US20110123534 Novel compounds for modulating neovascularisation and methods of treatment using these compounds
05/26/2011US20110123533 Using EGFRvIII to Identify and Target Cancer Stem Cells
05/26/2011US20110123532 Method for Making Heteromultimeric Molecules
05/26/2011US20110123531 Combination therapy
05/26/2011US20110123525 Anti-angiogenic therapy
05/26/2011US20110123524 Methods for treating hematopoietic malignancies
05/26/2011US20110123523 Antibodies against erbb3 and uses thereof
05/26/2011US20110123522 Methods of treating cancer using anti cd24 antibodies
05/26/2011US20110123516 Nitrogenated derivatives of pancratistatin
05/26/2011US20110123505 Method of producing reduced coenzyme q10 and method of stabilizing the same
05/26/2011US20110123494 Treatment with anti-vegf antibodies
05/26/2011US20110123492 Immunity-inducing agent
05/26/2011US20110123488 Method of Treatment for Cancers Associated with Elevated HER2 Levels
05/26/2011US20110123486 Methods of treating multiple myeloma and resistant cancers
05/26/2011US20110123484 Methods and compositions for treating fus1 related disorders
05/26/2011US20110123483 Hmgb1 for cancer treatment
05/26/2011US20110123480 Chimeric proteins and uses thereof
05/26/2011US20110123458 Polymer-metal complex composite having mri contrast ability and mri contrasting and/or antitumor composition using the same
05/26/2011US20110123457 Conjugates of 19f mr imaging tracers and chemotherapeutic agents for drug quantification and drug dose individualization
05/26/2011US20110123452 Metal oligomers and polymers and their use in biology and medicine
05/26/2011US20110123451 Method for Cell Delivery Using Targeted Liposomes Associated with a Hemolysin
05/26/2011US20110123448 Oil body carriers, uses in target therapy and/or detection of the same, and fusion proteins comprised therein
05/26/2011US20110123447 Method of providing human tumor-specific antibodies
05/26/2011US20110123444 Use of radioactively labelled molecule specifically binding to ED-B fibronection in a method of treatment of Hodgkin lymphoma
05/26/2011US20110123442 Tumor specific antibodies and uses therefor
05/26/2011US20110123441 Novel greb1a monoclonal antibody
05/26/2011US20110123440 Altered Antibody FC Regions and Uses Thereof
05/26/2011US20110123437 Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
05/26/2011US20110123436 Dock-and-Lock (DNL) Complexes for Delivery of Interference RNA
05/26/2011US20110123435 Compounds for inhibiting ksp kinesin activity
05/26/2011US20110123434 Combination therapies comprising quinoxaline inhibitors of p13k-alpha for use in the treatment of cancer
05/26/2011DE102010039912A1 Use of ginger in feed in a specified daily amount to reduce cortisol levels in the blood of the horse, e.g. for the treatment of equine Cushing's syndrome
05/26/2011DE102009054302A1 Chinazolinderivate Quinazoline derivatives
05/26/2011CA2818237A1 Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
05/26/2011CA2792198A1 Macrocyclic lactone derivatives for the treatment of cancer
05/26/2011CA2781935A1 Pyridine-pyridinone derivatives, preparation and therapeutic use thereof